US 12,118,414 B2
BCL-2 proteins degraders for cancer treatment
Guangrong Zheng, Little Rock, AR (US); Daohong Zhou, Little Rock, AR (US); Xuan Zhang, Little Rock, AR (US); Sajid Khan, Little Rock, AR (US); Yonghan He, Little Rock, AR (US); and Peiyi Zhang, Little Rock, AR (US)
Assigned to BIOVENTURES, LLC, Little Rock, AR (US)
Appl. No. 16/962,816
Filed by BioVentures, LLC, Little Rock, AR (US)
PCT Filed Jan. 22, 2019, PCT No. PCT/US2019/014545
§ 371(c)(1), (2) Date Dec. 20, 2021,
PCT Pub. No. WO2019/144117, PCT Pub. Date Jul. 25, 2019.
Claims priority of provisional application 62/620,219, filed on Jan. 22, 2018.
Prior Publication US 2021/0085675 A1, Mar. 25, 2021
Int. Cl. A61K 31/496 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G06J 1/00 (2006.01); G06N 3/063 (2023.01); G06N 5/04 (2023.01); G06N 10/00 (2022.01); A61N 5/06 (2006.01); A61N 5/10 (2006.01)
CPC G06J 1/00 (2013.01) [A61K 31/496 (2013.01); A61K 45/06 (2013.01); G06N 3/063 (2013.01); G06N 5/04 (2013.01); G06N 10/00 (2019.01); A61N 5/062 (2013.01); A61N 5/10 (2013.01)] 20 Claims
 
1. A method of selectively killing one or more cancer cells in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound or a salt of the compound, wherein the compound has the following chemical structure:

OG Complex Work Unit Chemistry